Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

Published 2014 View Full Article

Authors

Keywords

Journal

LANCET ONCOLOGY

Volume 15, Issue 6, Pages 569-579

Publisher

Elsevier BV

Online

2014-04-14

DOI

10.1016/s1470-2045(14)70118-4

Ask authors/readers for more resources

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

LANCET ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Add your recorded webinar

Create your own webinar